[Form 4] Organogenesis Holdings Inc. Insider Trading Activity

Rhea-AI Filing Summary

Organogenesis Holdings Inc. reporting person Brian Grow, the company's Chief Commercial Officer, disclosed transactions on 08/11/2025 involving both stock-option exercise and share transactions. The filing shows the exercise of a stock option that resulted in 4,060 Class A common shares acquired at an exercise price of $2.47, and it states that 100% of the shares subject to the option are fully vested and exercisable.

The Form 4 also reports a transaction involving 2,173 Class A common shares at a reported price of $4.615. The filing lists beneficial ownership figures of 674,550 and 672,377 Class A common shares on the respective lines, indicating the reporting person continues to hold hundreds of thousands of shares following these transactions.

Insights

Financial Analyst

TL;DR: Routine insider option exercise and related share transactions; modest net change in direct holdings.

The filing documents an exercise of 4,060 shares via a stock option with a $2.47 exercise price and a separate transaction of 2,173 shares at $4.615, both dated 08/11/2025. The option is fully vested and exercisable, per the filing. Net movement across the reported lines is the difference between those amounts (+1,887 shares), while beneficial ownership is reported in the 672k–674k range. For investors, this appears to be a routine liquidity and option-exercise event rather than a material corporate change.

Corporate Governance Expert

TL;DR: Disclosure aligns with Section 16 reporting; no governance red flags in the transactions disclosed.

The Form 4 identifies Brian Grow as the reporting officer and shows a fully vested option exercise converting to 4,060 Class A shares at $2.47. A related line reports 2,173 Class A shares at $4.615. The filing includes explicit beneficial ownership counts on the reported lines (674,550 and 672,377). The submission appears complete for the transactions reported and follows expected insider-disclosure practice.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grow Brian

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/11/2025		M		4,060	A	$2.47	674,550	D
Class A Common Stock	08/11/2025		F		2,173	D	$4.615	672,377	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.47	08/11/2025		M			4,060	(1)	08/11/2025	Class A Common Stock	4,060	$0	0	D

Explanation of Responses:

1. 100% of the shares subject to the option are fully vested and exercisable.

	/s/ William R. Kolb, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.